We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel Blood Test Developed for Alzheimer's Diagnosis

By LabMedica International staff writers
Posted on 30 Mar 2016
Print article
Image: The Vertex 70v Fourier-transform infrared (FTIR) spectrometer (Photo courtesy of Bruker Optics GmbH).
Image: The Vertex 70v Fourier-transform infrared (FTIR) spectrometer (Photo courtesy of Bruker Optics GmbH).
A blood test has been developed that may potentially facilitate detection of Alzheimer's disease at an early stage and it is based on an immuno-chemical analysis using an infrared sensor.

A major problem of Alzheimer's disease (AD) diagnosis is the fact that, by the time the first clinical symptoms appear, massive irreversible damage to the brain has already occurred and at that point, symptomatic treatment is the only available option.

Scientists at the Ruhr-University Bochum (Germany) and their colleagues analyzed the secondary structure of Amyloid-beta (Aβ) peptide in cerebrospinal fluid (CSF) and blood plasma of 141 patients which was measured with an immuno-infrared-sensor. The sensor's surface is coated with highly specific antibodies which extract biomarkers for Alzheimer's from the blood or the CSF, taken from the lower part of the back. The infrared sensor analyses of the biomarkers showed pathological changes, which can take place more than 15 years before any clinical symptoms appear. A Vertex 70v Fourier-transform infrared (FTIR) spectrometer (Bruker Optics GmbH; Ettlingen, Germany), equipped with a liquid nitrogen cooled mercury cadmium telluride (MCT) detector and water cooled, high efficiency mid- infrared (MIR) source was used.

The team achieved a diagnostic precision of 84% in the blood and 90% in cerebrospinal fluid, compared with the clinical gold standard. The test revealed an increase of misfolded biomarkers as spectral shift of Amyloid beta band below threshold, thus diagnosing AD. The results suggest that even in pre-dementia stages, an increased concentration of misfolded Amyloid beta peptides can be detected in body fluids. Additionally, a preliminary proof-of-concept study indicated an amide I band shift below the marker band already in patients with mild cognitive impairment due to AD. The presented immuno-IR-sensor method represents a promising, simple, robust, and label-free diagnostic tool for CSF and blood analysis.

Klaus Gerwert, PhD, a professor of Biophysics and a senior author of study, said, “We do not merely select one single possible folding arrangement of the peptide; rather, we detect how all existing Amyloid beta secondary structures are distributed, in their healthy and in their pathological forms. Tests that analyze Amyloid beta peptide are already available with so-called enzyme-linked immunosorbent assays (ELISA). They identify the total concentration, percentage of forms of different length, as well as the concentration of individual conformations in body fluids; but they have not, as yet, provided information on the diagnostically relevant distribution of the secondary structures at once.” The study was published on February 1, 2016, in the journal Analytical Chemistry.

Related Links:

Ruhr-University Bochum
Bruker Optics GmbH 


New
Gold Member
Thyroid Stimulating Hormone Assay
TSH EIA 96 Test
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Serum Toxicology Benzodiazepine Assay
DRI Serum Toxicology Benzodiazepine Assay
New
Human Immunodeficiency Virus Assay
RealLine HIV Quantitative Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: Heart attacks could be ruled out early with a new test, according to researchers (Photo courtesy of Mindray)

New High-Sensitivity Cardiac Troponin Test Quickly Rules Out Heart Attack

Patients arriving at an emergency department with symptoms like chest or arm pain, indicative of a potential heart attack, often prefer the comfort of home over a hospital bed—especially if they can be... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Immunology

view channel
Image: An immune response is initiated when an antigen-presenting cell (pink) presents foreign material to a T-cell (blue) (Photo courtesy of JAX)

Advanced Imaging Method Maps Immune Cell Connections to Predict Cancer Patients Survival

A growing tumor is influenced not only by the tumor cells themselves but also by the surrounding tissue, which alters its biology. Immune cells communicate by transferring vital signaling proteins to their... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.